Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 1/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.69 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.69 |
| ▸ | PDE10A | Q9Y233 | 14/20 | 0.54 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.39 |
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.39 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL898928 | 0.82 | NR1I2 (1.00) | NR1I2CYP3A4CYP2C9KCNH2PDE10A | |
| SCHEMBL902849 | 0.80 | NR1I2 (0.59) | NR1I2CYP3A4CYP2C9KCNH2PDE10A | |
| SCHEMBL902819 | 0.80 | NR1I2 (0.61) | NR1I2CYP3A4CYP2C9KCNH2PDE10A | |
| SCHEMBL15021722 | 0.74 | PDE10A (0.66) | NR1I2CYP3A4CYP2C9KCNH2PDE10A | |
| SCHEMBL899996 | 0.74 | PDE10A (0.48) | NR1I2CYP3A4CYP2C9KCNH2PDE10A | |
| SCHEMBL899888 | 0.73 | PDE10A (0.67) | NR1I2CYP3A4CYP2C9KCNH2PDE10A | |
| SCHEMBL19751932 | 0.73 | PDE10A (0.66) | NR1I2CYP3A4CYP2C9KCNH2PDE10A | |
| SCHEMBL898782 | 0.73 | PDE10A (0.66) | NR1I2CYP3A4CYP2C9KCNH2PDE10A | |
| SCHEMBL902411 | 0.71 | PDE10A (0.72) | NR1I2CYP3A4CYP2C9KCNH2PDE10A | |
| SCHEMBL899964 | 0.70 | PDE10A (0.67) | NR1I2CYP3A4CYP2C9KCNH2PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2621276-B1 | 2-ALKOXY PYRIMIDINE PDE10 INHIBITORS | MERCK SHARP & DOHME (US) | 2017-12-27 | — | — | EP | claimed |
| US-8785467-B2 | Alkoxy pyrimidine PDE10 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-07-22 | — | — | US | claimed |
| EP-2621276-A2 | 2-ALKOXY PYRIMIDINE PDE10 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2013-08-07 | — | — | EP | claimed |
| US-20130158056-A1 | ALKOXY PYRIMIDINE PDE10 INHIBITORS | MERCK SHARP & DOHME LLC | 2013-06-20 | — | — | US | claimed |
| WO-2012044561-A2 | 2-ALKOXY PYRIMIDINE PDE10 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-04-05 | — | — | WO | claimed |
| EP-2621276-B1 | 2-ALKOXY PYRIMIDINE PDE10 INHIBITORS | MERCK SHARP & DOHME (US) | 2017-12-27 | — | — | EP | disclosed |
| EP-2621276-B1 | 2-ALKOXY PYRIMIDINE PDE10 INHIBITORS | MERCK SHARP & DOHME (US) | 2017-12-27 | — | — | EP | disclosed |
| US-8785467-B2 | Alkoxy pyrimidine PDE10 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-07-22 | — | — | US | disclosed |
| US-8785467-B2 | Alkoxy pyrimidine PDE10 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-07-22 | — | — | US | disclosed |
| US-8785467-B2 | Alkoxy pyrimidine PDE10 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-07-22 | — | — | US | disclosed |
| US-20130158056-A1 | ALKOXY PYRIMIDINE PDE10 INHIBITORS | MERCK SHARP & DOHME LLC | 2013-06-20 | — | — | US | disclosed |
| US-20130158056-A1 | ALKOXY PYRIMIDINE PDE10 INHIBITORS | MERCK SHARP & DOHME LLC | 2013-06-20 | — | — | US | disclosed |
| US-20130158056-A1 | ALKOXY PYRIMIDINE PDE10 INHIBITORS | MERCK SHARP & DOHME LLC | 2013-06-20 | — | — | US | disclosed |
| WO-2012044561-A2 | 2-ALKOXY PYRIMIDINE PDE10 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158056-A1 | ALKOXY PYRIMIDINE PDE10 INHIBITORS | PDE10A, PDE11A, PDE12 | NR1I2 4311/4885CYP3A4 3247/4885CYP2C9 2563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.